Immunosuppression trends in solid organ transplantation: The future of individualization, monitoring, and management

Immunosuppression regimens used in solid organ transplant have evolved significantly over the past 70 years in the United States. Early immunosuppression and targets for allograft success were measured by incidence and severity of allograft rejection and 1-year patient survival. The limited number of agents, infancy of human leukocyte antigen (HLA) matching techniques and lack of understanding of immunoreactivity limited the early development of effective regimens. The 1980s and 1990s saw incredible advancements in these areas, with acute rejection rates halving in a short span of time. However, the constant struggle to achieve the optimal balance between under- and overimmunosuppression is weaved throughout the history of transplant immunosuppression. The aim of this paper is to discuss the different eras of immunosuppression and highlight the important milestones that were achieved while also discussing this in the context of rational agent selection and regimen design. This discussion sets the stage for how we can achieve optimal long-term outcomes during the next era of immunosuppression, which will move from universal protocols to patient-specific optimization.

Automated summary

The evolution of immunosuppression regimens in solid organ transplants in the United States over the past 70 years has been marked by significant advancements but also ongoing challenges in achieving the optimal balance between under- and overimmunosuppression. The development of effective regimens has been limited by factors such as the limited number of agents, early stages of HLA matching techniques, and lack of understanding of immunoreactivity. Future directions in transplant immunosuppression aim to move towards patient-specific optimization for optimal long-term outcomes.